RCKT Aligns With FDA on Completing Phase II Study in Danon Disease

Rocket Pharmaceuticals reached alignment with the FDA on key Phase II study elements for RP-A501, its gene therapy candidate for Danon disease. The regulatory agreement supports completion of the clinical program and reduces development uncertainty, although no efficacy, safety, financial, or approval-timing data were disclosed.